Christopher J. Forlenza, MD
Pediatric Hematology/Oncology; Pediatric Leukemia and Lymphoma, Histiocytic Disorders
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Forlenza accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, New York University School of Medicine
Montefiore Medical Center/Albert Einstein College of Medicine
Memorial Sloan Kettering Cancer Center
Pediatrics, Pediatric Hematology/Oncology
I am a member of the MSK Kids team who specializes in the care of children and young adults with blood (hematologic) cancers, including leukemias and lymphomas. I specialize in the treatment of Hodgkin lymphoma that has come back (relapsed) after prior therapy. I also care for patients with histiocytic disorders, including Langerhans cell histiocytosis.
In addition to caring for patients, I am conducting research to develop and assess better treatments. My research focuses on the development of novel therapies and treatment approaches for patients with lymphoma, with aim to improve their outcomes and minimize long-term side effects. I am MSK’s institutional Principal Investigator for the Children’s Oncology Group, the nation’s largest collaborative clinical research organization focused on childhood cancers.
When I meet a patient and family, I approach them with honesty, regardless of their age. I emphasize that this journey is something we are embarking on together. I thoroughly review their treatment options, emphasizing how the therapies we now have for their cancer have evolved.
I chose this field because as a physician, I can be on the cutting-edge of exciting technologies and emerging therapies. I am able to develop strong bonds with our patients and their families through difficult times, which often last for years. I support children and young adults as they battle through the worst times of their lives and am enormously gratified when I am able to watch them develop into healthy and successful adults.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
- Clinical Trials Investigated by Dr. Forlenza
- A Phase I Study Assessing the Combination of Immunotherapy and Targeted Chemotherapy to Treat Relapsed or Persistent Hodgkin Lymphoma
- A Phase I Study of Venetoclax in Children and Young Adults with Persistent or Recurrent Cancers
- A Phase II International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
- A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy in Children and Young Adults with Classical Hodgkin Lymphoma
- A Phase III Study of Standard Chemotherapy with Either Nivolumab Immunotherapy or Brentuximab Vedotin to Treat Newly Diagnosed Advanced Classical Hodgkin Lymphoma
- A Study of RC-P as a Treatment for People with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Who Are Allergic to PEG-Asparaginase
- Stopping Tyrosine Kinase Inhibitor Treatment in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Molecular Remission
- Clinical Trials Co-Investigated by Dr. Forlenza
- A Phase II Study of CAR T-Cell Therapy in Children and Young Adults with High-Risk B-Cell Acute Lymphoblastic Leukemia with Minimal Residual Disease after Chemotherapy
- A Phase II Study of Dabrafenib plus Trametinib after Radiation Therapy for Newly Diagnosed High-Grade Glioma
- A Phase II Study of Inotuzumab Ozogamicin in Children and Young Adults with Recurrent or Persistent B-Cell Acute Lymphoblastic Leukemia
- A Phase III Study Comparing Standard Chemotherapy to Treatment with CPX-351 and/or Gilteritinib for Children Newly Diagnosed with Acute Myeloid Leukemia
- A Phase III Study Evaluating Less Intensive Ways to Treat Germ Cell Tumors
- A Phase III Study of Accelerated versus Standard Chemotherapy for Patients with Intermediate- and Poor-Risk Metastatic Germ Cell Tumors
- A Phase III Study of Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard-Risk or Down Syndrome B-Lymphoblastic Leukemia and Patients with Localized B-Lymphoblastic Lymphoma
- A Phase III Study of Imatinib plus Chemotherapy According to Disease Risk in Young Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- A Phase III Study of Selumetinib versus Carboplatin/Vincristine in Patients with Low-Grade Glioma
- A Phase III Study of Selumetinib versus Carboplatin/Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Forlenza’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Christopher J. Forlenza discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.